US Pharm. 2012;37(8):8.
Silver Spring, MD—The FDA has approved two new treatments for obesity, making them the first prescription drugs for long-term weight loss to enter the U.S. market since 1999. Both Belviq (lorcaserin) and Qsymia (phentermine and topiramate extended-release) are indicated for chronic weight management in obese (BMI ≥30) or overweight (BMI ≥27) adults with comorbid conditions such as hypertension, type 2 diabetes, or dyslipidemia. Belviq is manufactured by Arena Pharmaceuticals, and Qsymia is marketed by Vivus Inc. Both manufacturers will be required to conduct postmarketing studies, including long-term cardiovascular outcomes trials, to assess the risk for major adverse cardiac events such as heart attack and stroke.
To comment on this article, contact rdavidson@uspharmacist.com.
